Sung Shih-Hsien, Chen Tzu-Ching, Cheng Hao-Min, Lee Jia-Chun, Lang Hui-Chu, Chen Chen-Huan
Department of Medicine; ; Cardiovascular Research Center; ; Department of Medicine; ; Department of Public Health.
Institute of Hospital and Health Care Administration, National Yang-Ming University; ; Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Acta Cardiol Sin. 2017 Jan;33(1):10-19. doi: 10.6515/acs20160608a.
The aim of this propensity score-matched cohort study was to investigate the prognostic impacts of drug-eluting stents (DES) and bare-metal stents (BMS) in patients undergoing percutaneous coronary intervention (PCI).
We conducted a retrospective cohort study based on the National Health Insurance program. Patients who had undergone coronary stenting between Jan. 2007 and Dec. 2008 were recruited and monitored until the end of 2010. Subjects with either BMS or DES were matched 2:1 by propensity score, which adjusted for age, sex, stent number and Charlson comorbidity index (CCI). The Kaplan-Meier method and Cox regression models were used for prognostic analyses.
Among a total of 966 patients with a mean age of 66 years, 644 subjects had BMS and 322 subjects had DES. The incidence of myocardial infarction (MI) and death were significantly lower in the DES group as compared with the BMS group for the three-year follow-up duration. With adjustments for age, sex, premium-based monthly salary, levels of hospital care, stent number, CCI, medications, and acute coronary syndrome presentation in the index hospitalization, use of DES rather than BMS was associated with reduced adverse coronary events (hazard ratio and 95% confidence interval: 0.55, 0.38-0.81 in the whole population, and 0.44, 0.26-0.73 in the subgroup patients with stable coronary artery disease).
Implantation of DES was related to better outcomes than for BMS, in terms of reducing MI and mortality after PCI. The survival benefit for patients with DES was even greater in patients with stable coronary artery disease.
这项倾向评分匹配队列研究的目的是调查药物洗脱支架(DES)和裸金属支架(BMS)对接受经皮冠状动脉介入治疗(PCI)患者的预后影响。
我们基于国家健康保险计划进行了一项回顾性队列研究。纳入2007年1月至2008年12月期间接受冠状动脉支架置入术的患者,并随访至2010年底。根据倾向评分将接受BMS或DES的受试者按2:1进行匹配,该评分对年龄、性别、支架数量和查尔森合并症指数(CCI)进行了调整。采用Kaplan-Meier法和Cox回归模型进行预后分析。
在总共966例平均年龄为66岁的患者中,644例接受BMS,322例接受DES。在三年随访期内,DES组的心肌梗死(MI)和死亡发生率显著低于BMS组。在对年龄、性别、基于保费的月工资、医院护理水平、支架数量、CCI、药物治疗以及首次住院时的急性冠状动脉综合征表现进行调整后,使用DES而非BMS与不良冠状动脉事件减少相关(风险比和95%置信区间:总体人群中为0.55,0.38 - 0.81;稳定冠状动脉疾病亚组患者中为0.44,0.26 - 0.73)。
就降低PCI术后的MI和死亡率而言,DES植入术的预后优于BMS。DES对稳定冠状动脉疾病患者的生存益处更大。